<DOC>
	<DOCNO>NCT01665937</DOCNO>
	<brief_summary>STA-9090 work inhibit function protein tumor cell call Hsp90 . Hsp90 think play role tumor growth . By interfere protein 's function , STA-9090 may help kill tumor cell . This drug use research study information study suggest agent may help slow tumor growth HCC . The purpose research study find high dose STA-9090 safely give participant advance HCC . The investigator also get information safety STA-9090 perform test learn STA-9090 affect body .</brief_summary>
	<brief_title>STA-9090 Patients With Advanced Hepatocellular Cancer</brief_title>
	<detailed_description>Study treatment give 4-week time period call cycle . Patients receive ST-9090 weekly first 3 week cycle treatment fourth week . STA-9090 give intravenous ( IV ) infusion . IV infusion occur IV catheter ( tube ) place vein . Each infusion last 60 minute . During cycle patient blood test , pregnancy test , EKG . Twenty thirty day last dose , patient return physical exam , blood test , urine test , EKG , CT MRI chest abdomen .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm hepatocellular carcinoma Measurable disease Life expectancy great 3 month ECOG performance status 0 1 BCLC Stage C disease Lab value must within limit outline protocol ChildPugh score &lt; /= 6 CLIP score 03 Must agree use adequate contraception Chemotherapy radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier Receiving investigational agent Known brain metastasis unless treat radiographically clinically stable without steroid anticonvulsant medication least 4 week prior first dose STA9090 History allergic reaction attribute compound similar chemical biologic composition STA9090 Surgery , radiotherapy , lesion ablative procedure area measurable disease Major surgery within 4 week prior first dose STA9090 Poor venous access study drug administration would require peripheral central indwell catheter study drug administration History severe allergic hypersensitivity reaction excipients ( e.g. , Polyethylene glycol [ PE ] 300 Polysorbate 80 ) Baseline QTc &gt; 450 msec previous history QT prolongation take medication Ventricular ejection fraction &lt; /= 55 % baseline Treatment chronic immunosuppressant Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant breastfeed History different malignancy unless diseasefree least 5 year deem investigator low risk recurrence . HIVpositive individual combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>advanced liver cancer</keyword>
	<keyword>advanced hepatocellular cancer</keyword>
</DOC>